FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Conor O'Shea

Research Profile

Chemicals & Drugs

Procedures

Devices

Stents

Disorders

Concepts & Ideas

Geographic Areas

United States

Co-author Network

Publications

TOP 3
Rajendra H Mehta; J Conor O'Shea; Amanda L Stebbins; Christopher B Granger; Paul W Armstrong; Harvey D White; Eric J Topol; Robert M Califf; E Magnus Ohman
Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysis.
Mina Madan; Janarthan Nikhil; Anne S Hellkamp; Karen S Pieper; Marino Labinaz; Eric A Cohen; Christopher E Buller; Warren J Cantor; Peter H Seidelin; John Ducas; Ronald G Carere; Madhu K Natarajan; J Conor O'Shea; James E Tcheng
Effect of operator and institutional volume on clinical outcomes after percutaneous coronary interventions performed in Canada and the United States: a brief report from the Enhanced Suppression of the Platelet glycoprotein IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) study.
James E Tcheng; Ing Haan Lim; Shankar Srinivasan; Joseph Jozic; C Michael Gibson; J Conor O'Shea; JA Puma; Daniel I Simon
Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Conor O'Shea (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Rajendra H Mehta; J Conor O'Shea; Amanda L Stebbins; Christopher B Granger; Paul W Armstrong; Harvey D White; Eric J Topol; Robert M Califf; E Magnus Ohman
Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysis.
Journal of the American College of Cardiology 2011;57(2):138-46.
2009: Mina Madan; Janarthan Nikhil; Anne S Hellkamp; Karen S Pieper; Marino Labinaz; Eric A Cohen; Christopher E Buller; Warren J Cantor; Peter H Seidelin; John Ducas; Ronald G Carere; Madhu K Natarajan; J Conor O'Shea; James E Tcheng
Effect of operator and institutional volume on clinical outcomes after percutaneous coronary interventions performed in Canada and the United States: a brief report from the Enhanced Suppression of the Platelet glycoprotein IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) study.
The Canadian journal of cardiology 2009;25(8):e269-72.
2009: James E Tcheng; Ing Haan Lim; Shankar Srinivasan; Joseph Jozic; C Michael Gibson; J Conor O'Shea; JA Puma; Daniel I Simon
Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial.
Circulation. Cardiovascular interventions 2009;2(1):43-51.
2007: Jean-Pierre Dery; Mark E Campbell; Jasmine Mathias; Karen S Pieper; Robert A Harrington; Mina Madan; C Michael Gibson; Thaddeus R Tolleson; J Conor O'Shea; James E Tcheng
Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2007;70(1):43-50.
2006: J Conor O'Shea; Robert M Califf
24-hour ambulatory blood pressure monitoring.
American heart journal 2006;151(5):962-8.
2006: Joseph A Puma; Lesan T Banko; Karen S Pieper; Terrence J Sacchi; J Conor O'Shea; Jean Pierre Dery; James E Tcheng
Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.
Journal of the American College of Cardiology 2006;47(4):715-8.
2005: Warren J Cantor; Mina Madan; J Conor O'Shea; Robert J Chisholm; Henry K Lui; David J Cohen; Robert L Feldman; Robert Green; Anne S Hellkamp; Michael M Kitt; James E Tcheng
Bailout use of platelet glycoprotein IIb-IIIa inhibition during coronary stent implantation: observations from the ESPRIT trial.
The Journal of invasive cardiology 2005;17(7):360-4.
2004: Mina Madan; Marino Labinaz; Eric A Cohen; Christopher E Buller; Warren J Cantor; Peter H Seidelin; John Ducas; Ronald G Carere; Madhu K Natarajan; Karen S Pieper; Gail E Hafley; J Conor O'Shea; Michael M Kitt; Robert M Califf; James E Tcheng
A comparison of clinical outcomes between Canadian and American patients after nonurgent coronary stenting.
The Canadian journal of cardiology 2004;20(13):1343-9.
2004: Abdallah G Rebeiz; Jean-Pierre Dery; Anastasios A Tsiatis; J Conor O'Shea; Brent A Johnson; Anne S Hellkamp; Karen S Pieper; Ian C Gilchrist; James Slater; J Brent Muhlestein; Diane Joseph; Michael M Kitt; James E Tcheng
Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy).
The American journal of cardiology 2004;94(7):926-9.
2004: Warren J Cantor; James E Tcheng; James C Blankenship; J Conor O'Shea; Karen S Pieper; Douglas A Criger; Mina Madan; John Ducas; William S Sheldon; Mark A Tannenbaum; Jack E Smith; Michael M Kitt; Ian C Gilchrist
Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experience.
The Journal of invasive cardiology 2004;16(9):475-81.
2004: J Conor O'Shea; Judith M Kramer; Robert M Califf; Eric D Peterson
Part I: Identifying holes in the safety net.
American heart journal 2004;147(6):977-84.
2003: James E Tcheng; Mina Madan; J Conor O'Shea; Eric A Cohen; Christopher E Buller; A Michael Lincoff; Jeffrey J Popma; Paul S Teirstein; Michael M Kitt; Todd J Lorenz; Sally Greenberg; NORMAN FOST; Robert M Califf
Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention.
Journal of interventional cardiology 2003;16(2):97-105.
2003: Thaddeus R Tolleson; J Conor O'Shea; John A Bittl; William B Hillegass; Kathryn A Williams; Glenn Levine; Robert A Harrington; James E Tcheng
Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial.
Journal of the American College of Cardiology 2003;41(3):386-93.
2003: Donal N Reddan; J Conor O'Shea; Ian J Sarembock; Kathryn A Williams; Karen S Pieper; Edward Santoian; William F Owen; Michael M Kitt; James E Tcheng
Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial).
The American journal of cardiology 2003;91(1):17-21.
2002: J Conor O'Shea; Robert G Wilcox; Allan M Skene; Amanda L Stebbins; Christopher B Granger; Paul W Armstrong; Christoph Bode; Diego Ardissino; Hakan Emanuelsson; Philip E Aylward; Harvey D White; Zygmunt Sadowski; Eric J Topol; Robert M Califf; Erik Ohman
Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone.
The American journal of cardiology 2002;90(12):1374-7.
2002: Jean-Pierre Dery; J Conor O'Shea; James E Tcheng
Eptifibatide in percutaneous coronary intervention. A review.
Minerva cardioangiologica 2002;50(5):531-46.
2002: Laura S Fernandes; James E Tcheng; J Conor O'Shea; Bonnie Weiner; Todd J Lorenz; Cindy Pacchiana; Lisa G Berdan; Kelly Maresh; Diane Joseph; Mina Madan; Tift Mann; Rakhi Kilaru; Judith S Hochman; Neal S Kleiman
Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.
Journal of the American College of Cardiology 2002;40(6):1085-91.
2002: J Conor O'Shea; James E Tcheng
Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa.
Expert opinion on pharmacotherapy 2002;3(8):1199-210.
2002: J Conor O'Shea; Christopher E Buller; Warren J Cantor; A Bleakley Chandler; Eric A Cohen; David J Cohen; Ian C Gilchrist; Neal S Kleiman; Marino Labinaz; Mina Madan; Gail E Hafley; Robert M Califf; Michael M Kitt; John Strony; James E Tcheng
Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.
JAMA : the journal of the American Medical Association 2002;287(5):618-21.
2002: David E Kandzari; Joseph Kay; J Conor O'Shea; Benjamin H Trichon; Mark P Donahue; Lawrence Liao; Sunil V Rao
Highlights from the American Heart Association annual scientific sessions 2001: November 11 to 14, 2001.
American heart journal 2002;143(2):217-28.
2002: David J Cohen; J Conor O'Shea; Cindy M Pacchiana; Glenn Levine; Ian J Sarembock; James Slater; Eric Conn; Jack Smith; James E Tcheng
In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin.
The American journal of cardiology 2002;89(1):61-4.
2001: James E Tcheng; J D Talley; J Conor O'Shea; Ian C Gilchrist; Neal S Kleiman; Cindy L Grines; C J Davidson; A Michael Lincoff; Robert M Califf; L K Jennings; Michael M Kitt; Todd J Lorenz
Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).
The American journal of cardiology 2001;88(10):1097-102.
2001: James E Tcheng; John Strony; Todd J Lorenz; J Conor O'Shea
ESPRIT in context: pharmacology matters!
European heart journal 2001;22(21):1965-7.
2001: James C Blankenship; G Tasissa; J Conor O'Shea; Elias A Iliadis; F A Bachour; David J Cohen; Henry K Lui; Tift Mann; E Cohen; James E Tcheng
Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial.
Journal of the American College of Cardiology 2001;38(3):653-8.
2001: I C Gilchrist; J Conor O'Shea; T Kosoglou; L K Jennings; Todd J Lorenz; Michael M Kitt; Neal S Kleiman; D Talley; FV Aguirre; C Davidson; J Runyon; James E Tcheng
Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention.
Circulation 2001;104(4):406-11.
2001: J Conor O'Shea; D L DeMets
Statistical issues relating to international differences in clinical trials.
American heart journal 2001;142(1):21-8.
2001: J Conor O'Shea; Y Fu; W C Chang; Paul W Armstrong
A tale of two countries: Insights from the differences in Canadian/American patterns of care for patients with acute coronary syndromes.
American heart journal 2001;142(1):14-20.
2001: J Conor O'Shea; Gail E Hafley; Sally Greenberg; Vic Hasselblad; Todd J Lorenz; Michael M Kitt; John Strony; James E Tcheng
Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2001;285(19):2468-73.
2001: J Conor O'Shea; Robert M Califf
International differences in treatment effects in cardiovascular clinical trials.
American heart journal 2001;141(5):875-80.
2001: J Conor O'Shea; Robert M Califf
International differences in cardiovascular clinical trials.
American heart journal 2001;141(5):866-74.
2001: J Conor O'Shea; Robert M Califf
International differences in cardiovascular clinical trials. Introduction.
American heart journal 2001;141(5):864-5.
2001: D K McGuire; J Conor O'Shea; C K Dyke; E J Velazquez; Michael P Hudson
Highlights from the XXII congress of the European Society of Cardiology: August 26 to 30, 2000.
American heart journal 2001;141(1):164-72.
2000: J Conor O'Shea; James E Tcheng
Small-molecule glycoprotein IIb/IIIa inhibitors as adjunctive therapy in percutaneous coronary interventions.
Journal of thrombosis and thrombolysis 2000;10(3):211-5.
2000: J Conor O'Shea; Mina Madan; Warren J Cantor; Cindy M Pacchiana; Sally Greenberg; Diane M Joseph; Michael M Kitt; Todd J Lorenz; James E Tcheng
Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.
American heart journal 2000;140(6):834-9.
2000: D K McGuire; J Conor O'Shea; C K Dyke; David E Kandzari; M A East; Thaddeus R Tolleson
Highlights from the American College of Cardiology 49th Annual Scientific Sessions: March 12 to 15, 2000.
American heart journal 2000;140(1):181-8.
2000: J Conor O'Shea; Michael B. Murphy
Nocturnal blood pressure dipping: a consequence of diurnal physical activity blipping?
American journal of hypertension 2000;13(6 Pt 1):601-6.
2000: J Conor O'Shea; Michael B. Murphy
Electronic activity-monitor-derived sleeping and awake times and diurnal variation of blood pressure.
Blood pressure monitoring 2000;5(2):65-8.
2000: J Conor O'Shea; Michael B. Murphy
Ambulatory blood pressure monitoring: which arm?
Journal of human hypertension 2000;14(4):227-30.
1997: J Conor O'Shea; Michael B. Murphy
Factors confounding assessment of ambulatory blood pressure monitors, studied during formal evaluation of the Tycos Quiet-Trak.
American journal of hypertension 1997;10(2):175-80.